Drug Profile
PMN 310
Alternative Names: huPMN-310; PMN-310Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator ProMIS Neurosciences
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Amyloid beta-protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 11 Mar 2024 ProMIS Neurosciences has patent protection for PMN 310 covering immunogenic compositions of matter in USA, Japan, South Korea, India and Australia
- 11 Mar 2024 ProMIS Neurosciences has patent protection for PMN 310 covering two other Aß targets in USA and Japan
- 11 Mar 2024 ProMIS Neurosciences has patent protection for PMN 310 in USA, Australia and Japan